ROYALTY PHARMA

ROYALTY PHARMA

Royalty Pharma plc

Q1 2024 Financial Results

May 9, 2024

Forward Looking Statements & Non-GAAP Measures

This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither the delivery of this presentation at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This presentation contains statements that constitute "forward-looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "target," "forecast," "guidance," "goal," "predicts," "project," "potential," or "continue," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of the Company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its own internal research is reliable, such research has not been verified by any independent source. For further information, please see the Company's reports and documents filed with the U.S. Securities and Exchange Commission ("SEC") by visiting EDGAR on the SEC's website at www.sec.gov.

Also, the discussions during this conference call will include certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). Additional information regarding non-GAAP liquidity measures can be found on slide 27 and in the Company's earnings release furnished with its Current Report on Form 8-K dated May 9, 2024, which are available on the Company's website. Any non-GAAP liquidity measures presented are not, and should not be viewed as, substitutes for measures required by GAAP, have no standardized meaning prescribed by GAAP and may not be comparable to the calculation of similar measures of other companies.

Agenda

Key Highlights	Pablo Legorreta	Founder & Chief Executive Officer
Portfolio Update	Marshall Urist	EVP, Head of Research & Investments
Development-stage Pipeline	Chris Hite	EVP, Vice Chairman
Financial Results	Terrance Coyne	EVP, Chief Financial Officer
Conclusion	Pablo Legorreta	Founder & Chief Executive Officer
Q&A	Pablo Legorreta Terrance Coyne Chris Hite Marshall Urist	Founder & Chief Executive Officer EVP, Chief Financial Officer EVP, Vice Chairman EVP, Head of Research & Investments

Key Highlights

Pablo Legorreta

Founder & Chief Executive Officer

ROYALTY PHARMA

Business momentum continues in Q1 2024

1 Financial

Royalty Receipts grew +14% with Portfolio Receipts declining to $717m due to non-recurring milestone in Q1 2023

- Royalty Receipts are recurring cash inflows while milestones and other contractual receipts are more variable

2 Capital allocation

Announced transaction to acquire royalties on Sanofi's frexalimab in Phase 3 for MS for approximately $525m(1)

Capital Deployment of approximately $670m, including cash expected to be paid for frexalimab

Increased quarterly dividend by 5% with commitment to mid-single digit annual growth

3 Portfolio

Exciting development-stage portfolio with potential to generate significantly >$1bn in peak royalties(2)

Vast majority has blockbuster potential and in development by premier global marketers

Multiple key upcoming events for late-stage pipeline

4 Full year guidance

Portfolio Receipts expected to be $2,600m to $2,700m excluding future investments(3)

Royalty Receipts growth expected to be ~+5% to +9% excluding future investments(3)

MS: Multiple sclerosis

1. Includes estimated transaction costs. 2. Non-risk-adjusted 3. Portfolio Receipts guidance excludes contribution from transactions announced subsequent to the date of this presentation.

Impressive track record of strong growth since IPO

Portfolio Receipts
(year/year growth)



1. Growth rates are presented on a pro forma basis. See slide 27 for definition and additional information.

Portfolio Update

Marshall Urist, MD, PhD

Executive Vice President
Head of Research & Investments

ROYALTY PHARMA

Frexalimab - potential blockbuster in immune-mediated diseases

- Announced transaction to acquire royalty interest in Sanofi's frexalimab from ImmuNext (private biotech)
  - ~$525m in cash including estimated transaction costs
  - Entitled to high-single to low-double digit royalty on worldwide sales(1)
  - Royalty duration expected through 2041
  - Substantial potential milestone payments from Sanofi, including more than half related to the lead MS indication(2)
- Sanofi stated potential non-risk adjusted peak sales of >€5bn(3)
- Potential peak annual royalties of >$400m with attractive returns

Frexalimab peak sales projections

(non-risk adjusted)



MS: multiple sclerosis

1. Royalty Pharma will receive 100% of net royalties on annual worldwide net sales of frexalimab of up to $2.0 billion and share a minority of the royalties above this threshold with ImmuNext's former shareholders.
2. Potential milestone payments consist of regulatory and commercial milestones.
3. Sanofi R&D day, December 7, 2023.

Frexalimab - potential next generation I&I therapy with clear PoC

- Frexalimab – novel MoA (anti-CD40L) in Phase 3 development with broad potential in immune-mediated diseases
- Compelling proof of concept – Phase 2 results in NEJM showed potential high-efficacy, non-lymphocyte depleting MS therapy[1]
  - Significant reductions in new GdE+ T1 lesions at week 12
  - 96% of frexalimab high-dose participants were free of GdE+ T1 lesions at week 48 and experienced a low ARR of 0.04
  - Safe and generally well-tolerated
- Phase 3 results in MS and FDA filing expected in H2 2027
- Additional indications could significantly expand opportunity

Sanofi's frexalimab: potential pipeline-in-a-product[2]



I&I: inflammation and immunology; PoC: proof of concept; MoA: mechanism of action; NEJM: New England Journal of Medicine; GdE+: gadolinium-enhanced; ARR: annualized relapse rate; MS: multiple sclerosis; T1D: type 1 diabetes; SLE: systemic lupus erythematosus; FDA: Food & Drug Administration

1. Sanofi press releases, February 15, 2024 and April 17, 2024.
2. Sanofi R&D day, December 7, 2023.

Frexalimab - deep analysis supports our confidence

Strong efficacy

Phase 2 data demonstrate **significant reduction** of active brain lesions by MRI images and low clinical relapse rate over 48 weeks

Novel mechanism

Differentiated mechanism of immune inhibition beyond B cells - **a potential key safety differentiator** versus current high efficacy MS therapies



Data translatability

Positive Phase 2 in MS **highly predictive of Phase 3 outcome** - proprietary statistical analyses confirm Phase 3 **designed for success**

World Class Marketer

Sanofi has a deep history in MS and a strong **commitment to I&I** - will maximize the potential of frexalimab globally



Unmet need

RP claims analysis projects nearly 100,000 MS patients in the U.S. will have discontinued CD20 therapy by the time frexalimab launches

Frexalimab is a potential novel, high efficacy agent with a differentiated safety profile supported by a strong marketer

MRI: magnetic resonance imaging; MS: multiple sclerosis; I&I: inflammation and immunology

Frexalimab – clearly aligned with product selection framework

Royalty Pharma product selection framework	frexalimab	
Strong scientific rationale	Evidence suggests key role of CD40/CD40L in MS	✓
Significant impact on patients/caregivers	Potential high-efficacy, non-lymphocyte depleting MS therapy	✓
Conviction in probability of success	Phase 2 results showed sustained reduction of disease activity	✓
Mission and execution-oriented management	Sanofi ambition to become an immunology powerhouse	✓
Strong marketer, global commercial footprint	Sanofi is a premier marketer in immunology and neurology	✓
Clear commercial positioning	Potential high-efficacy, non-lymphocyte depleting MS therapy	✓
Potential for multiple indications	Clinical trials in multiple immune-mediated diseases	✓
First-in-class or best-in-class	First-in-class CD40-ligand approach in MS	✓
Long duration of exclusivity	Duration of royalty expected through 2041	✓

MS: multiple sclerosis

Development-stage Pipeline

Chris Hite

Executive Vice President
Vice Chairman

ROYALTY PHARMA

Exciting development-stage pipeline to drive long-term growth

1

High potential

15 development-stage therapies[(1)] with potential to generate peak annual royalties **significantly >$1bn**

Pipeline has grown from **3 to 15 therapies** since IPO, despite capital deployed weighted towards approved products

Vast majority has **blockbuster potential**, and in development by premier global biopharma companies

2

Lower risk

Development-stage pipeline supported by **lower-risk profile** as majority are in Phase 3 development or undergoing regulatory review

Product selection and unique deal structuring further mitigates risk

3

Unlocking value

Multiple potential **upcoming events** over the next 12-18 months

- **2024**: Phase 3 results expected for seltorexant, TEV-'749 (topline safety data), Tremfya[(2)]; potential FDA filings for aficamten and pelabresib and approval for KarXT
- **2025**: pivotal study results expected for Novartis' pelacarsen, a potentially practice-changing medicine for CV disease

CV: cardiovascular

1. Including frexalimab
2. Johnson & Johnson to present positive Phase 3 results for Tremfya in Crohn's disease at an upcoming medical meeting.

Healthy mix of approved and development-stage investments

Annual Capital Deployment



~$22.8 billion in cumulative Capital Deployment

(since 2012 – 2024 YTD)



Approved Development-stage

1. Including cash to be paid for frexalimab

Significant growth and diversity of development-stage pipeline

Pipeline evolution since IPO

(by number of therapies)



Strong diversity of pipeline

(by number of therapies)



1. Including frexalimab

Strong track record of investing in development-stage therapies

- Invested ~$9bn in development-stage therapies since 2012
  - Require strong proof of concept data
  - Broad landscape of opportunities
  - Not constrained by therapeutic area
  - Target returns in the teens
- 15 development-stage therapies in portfolio[1]
- History of identifying therapies with unmet and underserved patient needs

Capital Deployment on development-stage therapies[2, 3]

(since 2012)



Approved since acquisition

Evrysdi risdiplam
trikafta
Nurtec ODT
Tecfidera
imbruvica
TAZVERIK
TRODELVY
AIRSUPRA
Bosulif
Zavzpret

1. Including frexalimab
2. Reflects Capital Deployment for development-stage therapies from 2012 through 2024 year-to-date (including cash to be paid for frexalimab).
3. Not approved includes investments in omecamtiv, gantenerumab, otilimab, BCX9930, vosaroxin, palbociclib, ApiJect and Merck KGaA's anti-IL17 nanobody M1095.

Unique and powerful approach to development-stage investing

	Product selection		Deal structure	
Approach	Post proof of concept with strong evidence of clinical efficacy and safety Partnering directly with innovators provides unique insights into clinical program and sales potential		Risk mitigation strategies through clinical & regulatory milestones, royalty tiering, option periods, etc. Strong alignment with partner through co-funding on top R&D programs	
Examples	**KarXT** Investment after third positive registrational trial minimizes regulatory risk	**aficamten** Unique insights into clinical program through direct partnership with Cytokinetics	**frexalimab** Nearly half of purchase price potentially returned in higher probability milestones mitigates risk	**MK-8189** Modest initial investment with option to significantly scale funding after Phase 2b data

Unique approach to development-stage investing drives attractive returns while mitigating risk

Big products with world class marketers and large royalties

Therapy	Lead indication	Marketer	Potential first- or best-in-class	Potential peak sales (non risk adjusted)[3]	Potential peak royalties
Frexalimab[1]	multiple sclerosis	Sanofi	✓	>$5bn	>$400m
olpasiran	cardiovascular disease	Amgen	✓	>$3bn	>$250m
pelacarsen	cardiovascular disease	Novartis	✓	>$3bn	>$150m
seltorexant	depression	Johnson & Johnson	✓	$1-5bn	>$150m
aficamten	hypertrophic cardiomyopathy	Cytokinetics	✓	>$4bn	>$150m
KarXT	schizophrenia	Bristol Myers Squibb	✓	>$5bn	~$100m
TEV-'749	schizophrenia	Teva	✓	~$1bn	~$35m
pelabresib	myelofibrosis	Novartis[2]	✓	>$1bn	>$30m
Total (late-stage development):				**>$25bn**	**>$1.25bn**

Excludes high potential early-stage pipeline – trontinemab (Alzheimer's), MK-8189 (schizophrenia), etc.

Note: the midpoint is used where ranges are shown.
1. Transaction expected to close in May 2024 2. Novartis announced the acquisition of MorphoSys on February 5, 2024 which is expected to close in the first half of 2024. 3. Potential peak sales for frexalimab, pelacarsen, and seltorexant based on marketer guidance; potential peak sales for olpasiran, KarXT, aficamten, TEV-'749 and pelabresib based on analyst research estimates.

Financial Results

Terrance Coyne

Executive Vice President
Chief Financial Officer

ROYALTY PHARMA

Strong Royalty Receipts performance in Q1 2024

Royalty Receipts
($ in millions)



Milestones and other contractual receipts
($ in millions)



Portfolio Receipts
($ in millions)



1. See slide 27 for additional information

Efficient model generates substantial cash flow to reinvest

$ in millions	Q1 2024		% Portfolio Receipts	Comments
Royalty Receipts[1]	705	+14% YoY		Recurring cash inflows of our royalty portfolio
Milestones & other contractual receipts[1]	12	-98% YoY		More variable cash receipts
Portfolio Receipts	717	**-37% YoY**		Substantially all cash inflows of the business
Payments for operating and professional costs	-61		8.4%	
Adjusted EBITDA (non-GAAP)	656		**91.6%**	
Interest paid, net	-73			
Portfolio Cash Flow (non-GAAP)	584		**81.4%**	Measure of cash that can be redeployed into new royalties, pay down debt, or returned to shareholders
Capital Deployment	**-93**			Reflects cash payments during the period for new and previously announced transactions
Share count[2]	**597.5**			

Amounts may not add due to rounding.

YoY: year over year

1. Reported net of legacy non-controlling interests to facilitate increased transparency of individual royalty economics and milestones
2. Reflects weighted-average diluted Class A ordinary shares outstanding in millions.

Significant financial capacity for future royalty acquisitions

- Pro forma[1] cash and cash equivalents of $318m
  - $525m of cash to acquire frexalimab royalties
- $6.3bn investment grade debt outstanding
  - Total pro forma leverage of 2.6x[2]
  - Net pro forma leverage of 2.4x[3]
  - Undrawn $1.8bn revolving credit facility
- Moody's improved outlook from stable to positive
- Financial capacity of >$3.5 billion with cash on hand and additional leverage[4]

Cash and cash equivalents

($ in millions)



1. Pro forma cash reflects Royalty Pharma's approximately $525 million payment including estimated transaction costs to acquire royalties on frexalimab. 2. Total pro forma leverage is calculated as Total debt divided by Adjusted EBITDA. 3. Net pro forma leverage is calculated as Total debt less pro forma cash and equivalents divided by Adjusted EBITDA. 4. Calculated based on total leverage ratio of ~4.0x. Total leverage is calculated as Total debt divided by Adjusted EBITDA (as defined in credit agreement filed with the SEC). 5. Primarily relates to the acquisition of ecopipam and funding of TEV-'749. 6. Primarily reflects dividends on Class A ordinary shares and Class B ordinary shares.

Full year 2024 guidance[1,2]

	February 15, 2024	May 9, 2024	Comments
Portfolio Receipts excluding transactions announced subsequent to May 9, 2024[1,2]	**$2,600m - $2,700m**	**$2,600m - $2,700m** Royalty Receipts expected growth of 5% to 9% in 2024	• Strong portfolio performance and full year of incremental Evrysdi royalties, partially offset by Imbruvica and Tysabri • Milestones and other contractual receipts expected to decline from $599m in 2023 to ~$30m in 2024 • Reflects range of timing outcomes for launch of Promacta generics and biosimilar Tysabri • Assumes negligible foreign exchange impact[3]
Operating & professional costs	**~8.0% - 9.0%** of Portfolio Receipts	**~8.0% - 9.0%** of Portfolio Receipts	• Unique business model provides margin protection despite inflationary environment
Interest paid	**~$160m**	**~$160m**	• Assumes no issuance of additional debt • *De minimis* interest paid expected in Q2 and Q4 2024 • Excludes interest received, which was $6m in Q1 2024

1. See slide 27 for definitions and for additional information regarding Royalty Pharma's 2024 full-year financial guidance. 2. This guidance is as of May 9, 2024 and assumes no major unforeseen adverse events and excludes any potential contribution from transactions announced subsequent to that date. Furthermore, Royalty Pharma may amend its guidance in the event it engages in new royalty transactions which have a material near-term financial impact on the Company. See the information on slide 3, "Forward Looking Statements & Non-GAAP Measures," for factors that may impact the achievement of this guidance. 3. See slide 27 for additional discussion regarding the assumptions for estimated foreign exchange impacts.

Conclusion

Pablo Legorreta

Founder & Chief Executive Officer

ROYALTY PHARMA

Participating in most important waves of biopharma innovation



HIV: human immunodeficiency virus; MS: Multiple sclerosis; CV: Cardiovascular; oHCM: obstructive hypertrophic cardiomyopathy; AD: Alzheimer's disease
1. Acquisiton anticipated to close in May 2024

Footnotes

1) To aid in comparability, quarter-over-quarter growth in 2020 is calculated based on pro forma 2019 results, which adjusts certain cash flow line items as if Royalty Pharma's Reorganization Transactions (as described in the Company's final prospectus filed with the SEC on June 17, 2020 ("Prospectus")) and its initial public offering ("IPO") had taken place on January 1, 2019. The most significant difference between the pro forma and reported figures is the non-controlling interest attributable to legacy investors that resulted from the Reorganization Transactions.

2) Portfolio Receipts is a key performance metric that represents our ability to generate cash from our portfolio investments, the primary source of capital that we can deploy to make new portfolio investments. Portfolio Receipts is defined as the sum of royalty receipts and milestones and other contractual receipts. Royalty receipts include variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that is attributed to Royalty Pharma ("Royalty Receipts"). Milestones and other contractual receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to the legacy non-controlling interests, that is attributed to Royalty Pharma. Portfolio Receipts does not include proceeds from equity securities or marketable securities, both of which are not central to our fundamental business strategy.

   Portfolio Receipts is calculated as the sum of the following line items from our GAAP consolidated statements of cash flows: *Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities* and *Distributions from equity method investees* less *Distributions to legacy non-controlling interests - Portfolio Receipts*, which represent contractual distributions of Royalty Receipts and milestones and other contractual receipts to the Legacy Investors Partnerships and RPSFT.

3) Biohaven related payments include $475m in Portfolio Receipts from the Zavzpret milestone payment in Q1 2023.

4) Adjusted EBITDA is defined under the revolving credit agreement as Portfolio Receipts minus payments for operating and professional costs. Operating and professional costs reflect *Payments for operating and professional costs* from the statements of cash flows. See GAAP to Non-GAAP reconciliation in the Company's Current Report on Form 8-K dated May 9, 2024. See the Company's Annual Report on Form 10-K filed with SEC on February 15, 2024 for additional discussion on defined term.

5) Portfolio Cash Flow is defined under the revolving credit agreement as Adjusted EBITDA minus interest paid or received, net. See GAAP to Non-GAAP reconciliation in the Company's Current Report on Form 8-K dated May 9, 2024. See the Company's Annual Report on Form 10-K filed with SEC on February 15, 2024 for additional discussion on defined term.

6) Capital Deployment represents the total outflows that will drive future Portfolio Receipts and reflects cash paid at the acquisition date and any subsequent associated contractual payments reflected in the period in which cash was paid.

   Capital Deployment is calculated as the summation of the following line items from our GAAP consolidated statements of cash flows: *Investments in equity method investees, Purchases of available for sale debt securities, Acquisitions of financial royalty assets, Acquisitions of other financial assets, Milestone payments, Development-stage funding payments - ongoing, Development-stage funding payments - upfront and milestone* less *Contributions from legacy non-controlling interests - R&D*.

7) Foreign exchange impact represents an estimate of the difference in results that are attributable to fluctuations in currency exchange rates based on certain assumptions of prevailing exchange rates for the related period, contractual terms, geographies from which our royalties are derived, timing of payments and other factors. The marketers paying us royalties may not provide or may not be required to provide the breakdown of product sales by geography. Actual foreign exchange impact may be different than our estimates.

Financial Guidance footnote

8) Royalty Pharma has not reconciled its non-GAAP 2024 guidance to the most directly comparable GAAP measure, net cash provided by operating activities, at this time due to the inherent difficulty in accurately forecasting and quantifying certain amounts that are necessary for such reconciliation, including, primarily, payments for operating and professional costs, distributions from equity method investees, and interest received. The Company is not able to forecast on a GAAP basis with reasonable certainty all adjustments needed in order to project net cash provided by operating activities on a GAAP basis at this time.

Appendix

ROYALTY PHARMA

Strong Royalty Receipts growth and base business performance

Q1 2024 Portfolio Receipts



1. Base business is defined as royalties in Royalty Pharma's portfolio as of December 31, 2023. Base business excludes Evrysdi 2 contribution given first receipt was in Q1 2024. Base business includes negligible estimated foreign exchange impact. See slide 27 for additional discussion regarding the assumptions for estimated foreign exchange impacts.

Important events expected in 2024

Select year-to-date and expected upcoming events



OS: overall survival; RCC: renal cell carcinoma; mCRPC: metastatic castration-resistant prostate cancer; FDA: Food & Drug Administration; EMA: European Medicines Agency

1. Gilead press release, January 22, 2024. 2. Johnson & Johnson press release, May 1, 2024. 3. Teva press release, May 8, 2024. 4. Gilead Q1 earnings presentation, April 25, 2024. 5. Johnson & Johnson Q1 earnings presentation, April 16, 2024. 6. Exelixis Q1 earnings call, April 30, 2024. 7. www.clinicaltrials.gov. 8. Johnson & Johnson press release, March 11, 2024. 9. Johnson & Johnson press release, May 1, 2024. 10. Bristol Myers Squibb Q1 earnings press release, April 25, 2024. KarXT PDUFA date is September 26, 2024. 11. Novartis press release, February 5, 2024. 12. Cytokinetics Q1 earnings release, May 8, 2024.

Potential royalties on ~40 projects in late-stage development



HNSCC: head and neck squamous cell carcinoma; mCRPC: metastatic castration-resistant prostate cancer; AD: Alzheimer's disease; mUC: metastatic urothelial carcinoma; mNSCLC: metastatic non-small-cell lung carcinoma; oHCM: obstructive hypertrophic cardiomyopathy; TNBC: triple negative breast cancer; mBC; metastatic breast cancer; mEC: metastatic endometrial cancer; nOH: neurogenic orthostatic hypotension; MSA: multiple system atrophy; mTNBC: metastatic triple negative breast cancer; RCC: renal cell carcinoma; NET; neuroendocrine tumors; nHCM: non-obstructive hypertrophic cardiomyopathy; MDD: major depressive disorder; PsA: psoriatic arthritis; GHD: growth hormone deficiency

1. EVOKE-02. 2. High risk localized advanced prostate cancer prior to radical prostatectomy. 3. High risk localized advanced prostate cancer receiving primary radiation therapy. 4. EVOKE-03. 5. Johnson & Johnson submitted applications to the European Medicines Agency seeking to expand Marketing Authorization Application for Tremfya in ulcerative colitis and Crohn's disease on May 1, 2024.